Skinvisible (SKVI) EBITDA Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.03 Bn | 625.27 Bn | 17.26 Bn | 120.00 |
| 2 | AbbVie | 441.56 Bn | 434.99 Bn | 12.70 Bn | 531.00 |
| 3 | Merck | 364.45 Bn | 357.31 Bn | 12.21 Bn | 3,082.00 |
| 4 | Novartis Ag | 267.46 Bn | 259.77 Bn | 11.24 Bn | 842.00 |
| 5 | Pfizer | 158.77 Bn | 147.08 Bn | 10.94 Bn | 214.00 |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | -963.00 |
| 7 | Revolution Medicines | 44.15 Bn | 44.15 Bn | - | - |
| 8 | Incyte | 25.31 Bn | 20.77 Bn | 1.57 Bn | 2,139.00 |
| 9 | United Therapeutics | 21.29 Bn | 18.63 Bn | 683.80 Mn | -1,031.00 |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 12.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.00 |
| Mar 31, 2026 | 3,932.00 |
| Dec 31, 2025 | 7,094.00 |
| Sep 30, 2025 | -75,610.00 |
| Jun 30, 2025 | -276,669.00 |
| Mar 31, 2025 | -266,443.00 |
| Dec 31, 2024 | -403,321.00 |
| Sep 30, 2024 | -249,233.00 |
| Jun 30, 2024 | -290,942.00 |
| Mar 31, 2024 | -154,154.00 |
| Dec 31, 2023 | -275,533.00 |
| Sep 30, 2023 | 224,300.00 |
| Jun 30, 2023 | -224,496.00 |
| Mar 31, 2023 | -174,826.00 |
| Dec 31, 2022 | -126,538.00 |
| Sep 30, 2022 | -15,278.00 |
| Jun 30, 2022 | 113,730.00 |
| Mar 31, 2022 | 161,274.00 |
| Dec 31, 2021 | 126,065.00 |
| Sep 30, 2021 | 73,500.00 |